Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Koppula P, Zhuang L, Gan B. · 2021
Read Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. by Koppula P, Zhuang L, Gan B. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8310547.txt.
Introduction
Koppula, Zhuang, and Gan examine the cystine transporter SLC7A11 in cancer and therapy. The transporter imports cystine to build glutathione. Many cancers switch it to high levels.
High levels shield tumours from ferroptosis, an iron-driven cell death. That shield helps tumours grow. It also carries a steep metabolic cost. Such cancer cells grow dependent on glucose and glutamine. Those cravings are weaknesses therapy can target. The review maps both sides of the trait. It shows how one transporter can be armour and Achilles heel at once. Nutrient dependency is the cost side of the shield.
Catalog record
| CREATOR | Koppula P, Zhuang L, Gan B. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 108 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy By Pranavi Koppula, Li Zhuang, Boyi Gan Published in: Protein & Cell DOI: 10.1007/s13238-020-00789-5 ABSTRACT The cystine/glutamate antiporter SLC7A11 (also commonly known as xCT) functions to import cystine for glutathione biosynthesis and antioxidant defense and is overexpressed in multiple human cancers. Recent studies revealed that SLC7A11 overexpression promotes tumor growth partly through suppressing ferroptosis, a form of regulated cell death induced by excessive lipid peroxidation. However, cancer cells with high expression of SLC7A11 (SLC7A11high) also have to endure the significant cost associated with SLC7A11-mediated metabolic reprogramming, leading to glucose- and glutamine-dependency in SLC7A11high cancer cells, which presents potential metabolic vulnerabilities for therapeutic targeting in SLC7A11high cancer. In this review, we summarize diverse regulatory mechanisms of SLC7A11 in cancer, discuss ferroptosis-dependent and -independent functions of SLC7A11 in promoting tumor development, explore the mechanistic basis of SLC7A11-induced nutrient dependency in cancer cells, and conceptualize therapeutic strategies to target SLC7A11 in cancer treatment. This review will provide the foundation for further understanding SLC7A11 in ferroptosis, nutrient dependency, and tumor biology and for developing novel effective cancer therapies. INTRODUCTION Cysteine is a proteinogenic amino acid that has a versatile role in protein synthesis, posttranslational modification, and redox maintenance (Stipanuk et al., 2006; Combs and DeNicola, 2019). Cysteine serves as the rate-limiting precursor for glutathione, a tripeptide comprised of three amino acids—cysteine, glutamate, and glycine—and the most abundant cellular antioxidant. Cysteine can also act as an antioxidant itself as well as the precursor for other biomolecules with antioxidant properties, such as taurine and hydrogen sulfide (Stipanuk et al., 2006; Combs and DeNicola, 2019). Intracellular cysteine can be synthesized through de novo biosynthesis (via the transsulfuration pathway) or recycled through protein degradation. However, because cancer cells often experience high levels of oxidative stress (Trachootham et al., 2009; Chio and Tuveson, 2017), cysteine supply via de novo biosynthesis or protein catabolism generally cannot meet the high demand for antioxidant defense in cancer cells; therefore, most cancer cells mainly rely on obtaining cysteine from the extracellular environment through nutrient transporters. The intra- and extra-cellular redox environments are very different: while cells generally maintain a reducing environment in the cytosol, the extracellular environment is highly oxidizing. Consequently, extracellular cysteine is highly unstable with only around 30-minute half-life in culture media (Ishii and Bannai, 1985), and is quickly oxidized to cystine (the oxidized dimer form of cysteine). The concentration of extracellular cystine is higher than that of extracellular cysteine by an order of magnitude. Some cancer cells can still effectively take up extracellular cysteine through cysteine transporters under certain conditions; for example, due to the high availability of extracellular cysteine secreted from surrounding bone marrow stromal cells, chronic lymphocytic leukemia cells can actively import cysteine from the extracellular environment (Zhang et al., 2012). However, most cancer cells largely depend on the cystine transporter system xc− to import cystine, which is then converted to cysteine in the cytosol through an NADPH-consuming reduction reaction; cysteine is subsequently used to synthesize glutathione (as well as other biomolecules) (Fig. 1) (Stipanuk et al., 2006; Combs and DeNicola, 2019).Figure 1Structure and function of SLC7A11. System xc− functions as a cystine/glutamate antiporter that imports one molecule of cystine in exchange for one molecule of intracellular glutamate. System xc− is a heterodimer consisting of the light chain subunit SLC7A11 and the heavy chain subunit SLC3A2. SLC7A11 mediates the antiporter activity of system xc−, whereas SLC3A2 anchors SLC7A11 to the plasma membrane and maintains SLC7A11 protein stability. Extracellular cystine is imported into the cell through SLC7A11, and then is converted to cysteine through a NADPH-consuming reduction reaction. Subsequently, cysteine is utilized to synthesize GSH through a two-step process. Cysteine forms γ-glutamylcysteine in conjugation with glutamate in the first step catalyzed by γ-GCS. The second step involves GS-mediated enzymatic addition of a glycine molecule to produce GSH. Ferroptosis is induced by excessive accumulation of lipid hydroperoxides in cellular membrane. GPX4 uses GSH to reduce lipid hydroperoxides to lipid alcohols, thereby suppressing ferroptosis, through which GSH is oxidized to GSSG; GSSG is then converted back to GSH via GR-mediated reduction reaction, which consumes NADPH. γ-GCS: γ-glutamylcysteine synthetase, GS: glutathione synthetase, GPX4: glutathione peroxidase 4, GR: glutathione reductase, GSH: reduced glutathione, GSSG: oxidized glutathione, LOOH: lipid hydroperoxide, LOH: lipid alcohol The system xc− is a sodium-independent antiporter that exports intracellular glutamate and import extracellular cystine at a 1:1 ratio (Fig. 1) (Bannai, 1986; Conrad and Sato, 2012). It consists of two subunits linked via a disulfide bond, including the heavy chain subunit solute carrier family 3 member 2 (SLC3A2; also called CD98 or 4F2hc) and the light chain subunit solute carrier family 7 member 11 (SLC7A11; also commonly known as xCT). SLC7A11, a multi-pass transmembrane protein, mediates the cystine/glutamate antiporter activity in the system xc− (Sato et al., 1999; Koppula et al., 2018), whereas SLC3A2, a single transmembrane protein, is a chaperone to maintain SLC7A11 protein stability and appropriate membrane localization (Fig. 1) (Nakamura et al., 1999). Since SLC3A2 also serves as the chaperone for several other amino acid transporters, its function is not limited to cystine transport (Kandasamy et al., 2018). We will focus on SLC7A11 and refer to this cystine transporter as SLC7A11 throughout this review. The role of cystine uptake in maintaining cell survival was implicated many years ago by the observation that cystine deprivation in cell culture media can lead to significant cell death in many cancer cell lines (Eagle, 1955a, b); however, the nature of this cell death had remained unclear. It was later shown that cystine starvation results in glutathione depletion in cells and that cystine starvation-induced cell death can be rescued by antioxidant vitamin E, therefore indicating the involvement of an oxidative stress-induced cell death in this context (Bannai et al., 1977). In 2012, it was discovered that pharmacologic blockade of SLC7A11-mediated cystine uptake by compounds such as erastin induces a new form of cell death termed ferroptosis (Dixon et al., 2012). Ferroptosis is an iron-dependent form of regulated cell death induced by lethal accumulation of lipid peroxides in the cellular membrane, and is mechanistically and morphologically distinct from other forms of regulated cell death such as apoptosis and necroptosis (Stockwell et al., 2017; Stockwell and Jiang, 2020). Cells have evolved various defense mechanisms to detoxify these toxic lipid peroxides, prominent among which is glutathione peroxidase 4 (GPX4), a GPX family member that uses reduced glutathione (GSH) as a co-factor to detoxify lipid peroxides to lipid alcohols, thereby suppressing ferroptosis (Fig. 1) (Friedmann Angeli et al., 2014; Yang et al., 2014). As noted above, cysteine is the rate-limiting precursor for GSH synthesis, and intracellular cysteine is mainly supplied by SLC7A11-mediated cystine uptake. Consistent with this, it was shown that removing cystine from cell culture media or SLC7A11 inactivation by genetic ablation or pharmacologic inhibition induces potent ferroptosis in many cancer cells; conversely, SLC7A11 overexpression in cancer cells promotes GSH biosynthesis and ferroptosis resistance (Dixon et al., 2012; Jiang et al., 2015; Zhang et al., 2018b). These studies together establish a critical role of SLC7A11-mediated cystine uptake in suppressing ferroptosis and maintaining cell survival under oxidative stress conditions. In recent years, ferroptosis as a new cell death mechanism has sparked great interest in the